par Dremier, Sarah ;Coulonval, Katia ;Perpete, Sandrine ;Vandeput, Fabrice ;Fortemaison, Nathalie ;Van Keymeulen, Alexandra ;Deleu, Sandrine ;Ledent, Catherine ;Clément, Serge ;Schurmans, Stéphane ;Dumont, Jacques Emile ;Lamy, Françoise ;Roger, Pierre P. ;Maenhaut, Carine
Référence Annals of the New York Academy of Sciences, 968, page (106-121)
Publication Publié, 2002-06
Référence Annals of the New York Academy of Sciences, 968, page (106-121)
Publication Publié, 2002-06
Article révisé par les pairs
Résumé : | Cyclic AMP has been shown to inhibit cell proliferation in many cell types and to activate it in some. The latter has been recognized only lately, thanks in large part to studies on the regulation of thyroid cell proliferation in dog thyroid cells. The steps that led to this conclusion are outlined. Thyrotropin activates cyclic accumulation in thyroid cells of all the studied species and also phospholipase C in human cells. It activates directly cell proliferation in rat cell lines, dog, and human thyroid cells but not in bovine or pig cells. The action of cyclic AMP is responsible for the proliferative effect of TSH. It accounts for several human diseases: congenital hyperthyroidism, autonomous adenomas, and Graves' disease; and, by default, for hypothyroidism by TSH receptor defect. Cyclic AMP proliferative action requires the activation of protein kinase A, but this effect is not sufficient to explain it. Cyclic AMP action also requires the permissive effect of IGF-1 or insulin through their receptors, mostly as a consequence of PI3 kinase activation. The mechanism of these effects at the level of cyclin and cyclin-dependent protein kinases involves an induction of cyclin D3 by IGF-1 and the cyclic AMP-elicited generation and activation of the cyclin D3-CDK4 complex. |